Oral Antidiabetic Drugs Market: 2014 - 2022

  • ID: 4429400
  • Report
  • 110 pages
  • Zion Market Research
1 of 3
The report covers forecast and analysis for the oral antidiabetic drugs market on a global and regional level. The study provides historic data of 2016 along with a forecast from 2017 to 2022 based on revenue (USD billion). The study includes drivers and restraints of the oral antidiabetic drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the oral antidiabetic drugs market on a global level.

In order to give the users a comprehensive view of the Oral antidiabetic drugs market, we have included a detailed competitive scenario and product portfolio of key vendors. To understand the competitive landscape in the market, an analysis of Porter's five forces model for the oral antidiabetic drugs market has also been included. The study encompasses a market attractiveness analysis, wherein the segments are benchmarked based on their market size, growth rate, and general attractiveness.

The study provides a decisive view on the oral antidiabetic drugs market by segmenting the market based on drugs class and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2017 to 2022. The drugs class segmentation includes sulfonylureas, meglitinides, biguanides, alpha-glucosidase inhibitors and others. The meglitinides class is further segmented into repaglinide and nateglinide. The regional segmentation includes the current and forecast demand for North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. These regions are further sub-segmented into U.S., Canada, China, Japan, and Brazil.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global oral antidiabetic drugs market include Eli Lilly, Abbott, Biocon, Sanofi, Sunpharma, Novartis, Novo Nordisk, Merck and Pfizer.

This report segments the global oral antidiabetic drugs Market as follows:

Global Oral Antidiabetic Drugs Market: Drugs Class Analysis

- Sulfonylureas

- Glimepiride

- Gliclazide

- Glyburide

- Others

- Meglitinides

- Repaglinide

- Nateglinide

- Biguanides

- Metformin

- Others

- Alpha-glucosidase inhibitors

- Acarbose

- Voglibose

- Others

- Others

Global Oral Antidiabetic Drugs Market: Regional Segment Analysis

- North America

- U.S.

- Canada

- Europe

- Asia Pacific

- China

- Japan

- Rest of Asia Pacific

- Latin America

- Brazil

- Middle East and Africa
READ MORE
Note: Product cover images may vary from those shown
2 of 3
  • Chapter 1. Introduction
    • 1.1. Report Description And Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Global Oral Anti-Diabetic Market, 2016 - 2022 (USD Billion)
    • 2.2. Global Oral Anti-Diabetic Market: Snapshot
  • Chapter 3. Oral Anti-Diabetic – Market Dynamics
    • 3.1. Introduction
    • 3.2. Value Chain Analysis
    • 3.3. Market Drivers
      • 3.3.1. Global Oral Anti-Diabetic Market Drivers: Impact Analysis
      • 3.3.2. Rising Prevalence Of Diabetes Mellitus
      • 3.3.3. Increase In Obesity
    • 3.4. Market Restraints
      • 3.4.1. Global Oral Anti-Diabetic Market Restraints: Impact Analysis
      • 3.4.2. High Cost of Drugs
    • 3.5. Opportunities
      • 3.5.1. Market Strength
    • 3.6. Porter's Five Forces Analysis
      • 3.6.1. Bargaining Power Of Suppliers
      • 3.6.2. Bargaining Power Of Buyers
      • 3.6.3. Threat From New Entrants
      • 3.6.4. Threat From New Substitutes
      • 3.6.5. Degree Of Competition
    • 3.7. Market Attractiveness Analysis
      • 3.7.1. Market Attractiveness Analysis, By Drug Class Segment
      • 3.7.2. Market Attractiveness Analysis, By Regional Segment
  • Chapter 4. Global Oral Anti-Diabetic Market – Competitive Landscape
    • 4.1. Company Market Share, 2016 (Subject To Data Availability)
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Type Launch
      • 4.2.3. Agreements, Partnerships, Collaborations And Joint Ventures
      • 4.2.4. Research And Development, Regional Expansion
    • 4.3. Type Portfolio
  • Chapter 5. Global Oral Anti-Diabetic Market – Drug Class Analysis
    • 5.1. Global Oral Anti-Diabetic Market: Drug Class Segment Overview
      • 5.1.1. Global Oral Anti-Diabetic Market Revenue Share, By Drug Class, 2016 And 2022
    • 5.2. Sulfonylureas
      • 5.2.1. Global Sulfonylureas Market, 2016 – 2022 (USD Billion)
      • 5.2.2. Glimepiride
        • 5.2.2.1. Glimepiride Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
      • 5.2.3. Gliclazide
        • 5.2.3.1. Gliclazide Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
      • 5.2.4. Glyburide
        • 5.2.4.1. Glyburide Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
      • 5.2.5. Others
        • 5.2.5.1. Others Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
    • 5.3. Meglitinides
      • 5.3.1. Global Meglitinides Market, 2016 – 2022 (USD Billion)
      • 5.3.2. Repaglinide
        • 5.3.2.1. Repaglinide Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
      • 5.3.3. Nateglinide
        • 5.3.3.1. Nateglinide Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
    • 5.4. Biguanides
      • 5.4.1. Global Biguanides Market, 2016 – 2022 (USD Billion)
      • 5.4.2. Metformin
        • 5.4.2.1. Metformin Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
      • 5.4.3. Others
        • 5.4.3.1. Others Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
      • 5.5. Alpha-glucosidase inhibitors
        • 5.5.1. Global Alpha-glucosidase inhibitors Market, 2016 – 2022 (USD Billion)
        • 5.5.2. Acarbose
          • 5.5.2.1. Acarbose Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
        • 5.5.3. Voglibose
          • 5.5.3.1. Voglibose Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
        • 5.5.4. Others
          • 5.5.4.1. Others Oral Anti-Diabetic Market Revenue, 2016 – 2022 (USD Billion)
  • Chapter 6. Global Oral Anti-Diabetic Market – Regional Segment Analysis
    • 6.1. Global Oral Anti-Diabetic Market: Regional Overview
      • 6.1.1. Global Oral Anti-Diabetic Market Revenue Share, By Region, 2016 And 2022
    • 6.2. North America
      • 6.2.1. North America Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022, (USD Billion)
      • 6.2.2. U.S.
        • 6.2.2.1. U.S. Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
      • 6.2.3. Canada
        • 6.2.3.1. Canada Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
    • 6.3. Europe
      • 6.3.1. Europe Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
      • 6.3.2. Germany
        • 6.3.2.1. Germany Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022, (USD Billion)
      • 6.3.3. France
        • 6.3.3.1. France Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022, (USD Billion)
      • 6.3.4. U.K.
        • 6.3.4.1. U.K. Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
    • 6.4. Asia Pacific
      • 6.4.1. Asia Pacific Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
      • 6.4.2. China
        • 6.4.2.1. China Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
      • 6.4.3. Japan
        • 6.4.3.1. Japan Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
      • 6.4.4. India
        • 6.4.4.1. India Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
    • 6.5. Latin America
      • 6.5.1. Latin America Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
      • 6.5.2. Brazil
        • 6.5.2.1. Brazil Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
    • 6.6. Middle East And Africa
      • 6.6.1. Middle East And Africa Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 – 2022 (USD Billion)
  • Chapter 7. Company Profile
    • 7.1. Abbott Laboratories
      • 7.1.1. Overview
      • 7.1.2. Financials
      • 7.1.3. Product Portfolio
      • 7.1.4. Business Strategy
      • 7.1.5. Recent Developments
    • 7.2. Biocon, Ltd
      • 7.2.1. Overview
      • 7.2.2. Financials
      • 7.2.3. Product Portfolio
      • 7.2.4. Business Strategy
      • 7.2.5. Recent Developments
    • 7.3. Eli Lilly and Company
      • 7.3.1. Overview
      • 7.3.2. Financials
      • 7.3.3. Product Portfolio
      • 7.3.4. Business Strategy
      • 7.3.5. Recent Developments
    • 7.4. Sun Pharma Industries, Ltd.
      • 7.4.1. Overview
      • 7.4.2. Financials
      • 7.4.3. Product Portfolio
      • 7.4.4. Business Strategy
      • 7.4.5. Recent Developments
    • 7.5. Novo Nordisk A/S
      • 7.5.1. Overview
      • 7.5.2. Financials
      • 7.5.3. Product Portfolio
      • 7.5.4. Business Strategy
      • 7.5.5. Recent Developments
    • 7.6. Pfizer
      • 7.6.1. Overview
      • 7.6.2. Financials
      • 7.6.3. Product Portfolio
      • 7.6.4. Business Strategy
      • 7.6.5. Recent Developments
    • 7.7. Sanofi
      • 7.7.1. Overview
      • 7.7.2. Financials
      • 7.7.3. Product Portfolio
      • 7.7.4. Business Strategy
      • 7.7.5. Recent Developments
    • 7.8. Novartis
      • 7.8.1. Overview
      • 7.8.2. Financials
      • 7.8.3. Product Portfolio
      • 7.8.4. Business Strategy
      • 7.8.5. Recent Developments
    • 7.9. Merck Group
      • 7.9.1. Overview
      • 7.9.2. Financials
      • 7.9.3. Product Portfolio
      • 7.9.4. Business Strategy
      • 7.9.5. Recent Development
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll